This study looks at how well a medicine called naldemedine works for people with cancer who become constipated while taking opioids. Opioids are medications prescribed to treat persistent or severe pain. Opioids can slow down the bowel and make it hard to pass stool. About 6 out of 10 people who use opioids have constipation. Laxatives such as lactulose or macrogol are described to help with this problem. If laxatives do not work, doctors may use special medicines called opioid blockers that act only in the gut. These medicines help relieve constipation without reducing pain relief. Naldemedine is one of these opioid blockers. It became available in the Netherlands in 2024 but is not yet widely used. The goal of this study is to learn how well naldemedine works in everyday care and how people feel while using it. Researchers will collect information on both medical results and participants' experiences.

开始日期2026-01-02

申办/合作机构

Viatris, Inc.

NCT07038551

/ Recruiting临床4期

Prophylactic Use of Naldemedine on Opioid-Induced Nausea and Vomiting in Patients With Cancer: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

Opioid analgesics can cause side effects such as constipation, nausea, and vomiting by acting on opioid receptors widely distributed in the peripheral nervous system. This can sometimes make it difficult to achieve and maintain pain relief and continue pain treatment. Among these side effects, nausea and vomiting are specifically referred to as opioid-induced nausea and vomiting (OINV). OINV is known to occur during the initial administration or dose escalation of opioid analgesics, and it not only decreases the quality of life for patients but also reduces adherence to opioid analgesics, which can have a negative impact on pain management. Therefore, appropriate management is crucial.
While the administration of conventional antiemetic drugs is recommended for the treatment of OINV, there is a lack of high-quality studies evaluating their effectiveness, and studies comparing treatment effects with a placebo have not been reported.
The objective is to verify the effectiveness of nalbuphine in preventing OINV in patients starting opioid analgesics for cancer

开始日期2025-06-06

申办/合作机构

International University of Health & Welfare

[+1]

NCT06334198

/ Unknown status临床2期IIT

The Effect of Naldemedine on Opioid-induced Bowel Dysfunction. An Investigator Initiated, Randomized, Double-blinded, Placebo-controlled, Cross-over Clinical Trial

Opioid-induced bowel dysfunction is a frequent condition during opioid therapy for chronic pain. Indeed, up to 90% of people on opioid treated patients experience constipation. Standard laxative treatment is often ineffective in opioid-induced constipation, but peripheral acting mu-receptor antagonists (PAMORAs) have the potential to block the effects of opioids in the gastrointestinal tract while preserving the central analgesic effect. In this study, we will investigated the effects of Naldemedine in preventing the development of opioid-induced bowel dysfunction and constipation during treatment with tramadol

开始日期2024-03-12

申办/合作机构

Aalborg University Hospital

100 项与纳地美定相关的临床结果

登录后查看更多信息

100 项与纳地美定相关的转化医学

登录后查看更多信息

100 项与纳地美定相关的专利（医药）

登录后查看更多信息

177

项与纳地美定相关的文献（医药）

2026-03-01·SUPPORTIVE CARE IN CANCER

Dose-dependent association of naldemedine and magnesium oxide in the management of opioid-induced constipation

Article

作者: Hoshino, Ryo ; Goto, Sakika ; Kobayashi, Ryo ; Suzuki, Akio ; Ishihara, Masashi ; Nakaya, Hinako ; Watanabe, Daichi

PURPOSE:

This study aimed to evaluate the efficacy and potential pharmacological interaction of naldemedine and magnesium oxide (MgO) in the management of opioid-induced constipation (OIC) in cancer patients, with a particular focus on the impact of different MgO doses on treatment outcomes.

METHODS:

A total of 171 patients who received opioid therapy were included in this study. The outcome variable was defecation. Daily defecation status during the observation period was extracted from electronic medical records. To assess the effects and potential interaction between naldemedine and MgO on defecation, a generalized estimating equations (GEE) model with a logit link function was used to account for within-patient clustering. Predicted probabilities of defecation were calculated based on the fitted GEE model.

RESULTS:

The probability of defecation increased with higher doses of MgO. Among patients receiving both MgO and naldemedine, the likelihood of defecation was significantly higher at MgO doses ≤ 1500 mg compared to those receiving MgO alone. However, at doses > 1500 mg, naldemedine did not add further benefit. Naldemedine was independently associated with improved bowel movements, regardless of MgO use. The association between MgO and defecation also strengthened with increasing doses. No significant interaction between naldemedine and MgO was observed at any dose.

CONCLUSION:

The concomitant use of MgO and naldemedine was associated with improved defecation, although no statistically significant interaction was detected. However, the added benefit of naldemedine may be limited at higher MgO doses. Naldemedine may be particularly effective in patients with constipation during opioid therapy that is insufficiently responsive to conventional laxatives, especially when an increase in MgO is difficult due to risks such as hypermagnesemia.

2026-02-01·United European Gastroenterology Journal

Naldemedine for the Prevention of Recurrent Acute Pancreatitis: A Randomised, Double‐Blind, Placebo‐Controlled Trial

Article

作者: Knoph, Cecilie S. ; Drewes, Asbjørn M. ; Cook, Mathias E. ; Novovic, Srdan ; Jørgensen, Maiken Thyregod ; Bruun, Niels H. ; Davidsen, Line ; Berner‐Hansen, Mark ; Olesen, Søren S. ; Frøkjær, Jens B. ; Schaffalitzky, Ove ; Mortensen, Michael B. ; Hadi, Amer ; Nielsen, Liv B. J.

ABSTRACT:

Background and aims:

No medications are currently approved for the prevention of recurrent acute pancreatitis. This trial evaluated whether naldemedine, a peripherally acting μ ‐opioid receptor antagonist, reduces the risk of acute pancreatitis in patients with recurrent acute pancreatitis.

Methods:

This was a multicentre, double‐blinded, placebo‐controlled randomised trial conducted at four Danish pancreatitis referral centres. Participants aged 18–75 years with recurrent acute pancreatitis, both with and without a diagnosis of chronic pancreatitis, were randomised to receive naldemedine 0.2 mg or a matching placebo daily for up to 12 months. The primary outcome was acute pancreatitis recurrence, defined by the revised Atlanta Criteria. Secondary outcomes included pain flares, gastrointestinal symptoms, and quality of life. At the end of follow‐up, the participant's global impression of change, safety and tolerability outcomes, new‐onset diabetes and pancreatic exocrine insufficiency were assessed.

Results:

74 participants (mean age: 46 years; 41% female) were randomised to naldemedine ( n = 36) or placebo ( n = 38). During a median follow‐up time of 365 days (IQR, 352–370), participants in the naldemedine group had a numerically lower risk of acute pancreatitis compared to placebo (HR 0.54; 95% CI, 0.29–1.01; p = 0.05). No differences were observed between the groups for secondary efficacy, safety, and tolerability outcomes. Participants treated with naldemedine for at least 1 year had a lower risk of acute pancreatitis (HR 0.49; 95% CI, 0.24–0.97; p = 0.04).

Conclusions:

Treatment with naldemedine was safe and well‐tolerated and may reduce the risk of recurrent acute pancreatitis. A larger confirmatory trial is needed to verify these findings.

Trial registration:

ClinicalTrials.gov Identifier: PAMORA‐RAP: NCT04966559

2025-10-01·MOLECULAR DIVERSITY

Repurposed pharmacotherapy: targeting cathepsin L with repurposed drugs in virtual screening

Article

作者: Foudah, Ahmed I ; Alqarni, Mohammed H ; Foudah, Ahmed I. ; Alqarni, Mohammed H. ; Khalid, Mohammad

Proteolytic enzymes are closely associated with cancer and are important in different phases, including tumor growth, angiogenesis, and metastasis. Despite efforts to target matrix metalloproteases (MMPs), clinical trials have often resulted in various side effects such as musculoskeletal pain, joint stiffness, and tendinitis, making them less optimal for chronic cancer treatment. Thus, there is a need for the identification of other protease targets that would provide different approaches towards the management of cancer. Of these targets, Cathepsin L (CatL) is a lysosomal cysteine protease that has been identified as a therapeutic target that is implicated in cancer development and metastasis. In this study, we performed an integrated approach of virtual screening and molecular dynamics (MD) simulations to identify the potential inhibitors of CatL from a library of drugs that have been used for different treatments. Towards this goal, we performed virtual screening of the DrugBank database and found two repurposed drugs, Irinotecan and Nilotinib, against CatL based on their docking profiles, favorable docking scores, and specific interaction with the CatL binding pocket. MD simulations of the Irinotecan and Nilotinib bound structures with CatL were carried out, and the analysis showed that both these compounds could function as CatL inhibitors as the protein-ligand interactions were stable for 300 ns. This study highlights the robustness of these drugs bound to CatL and indicates that they could be repurposed for the treatment of cancer. These findings endorse the use of computer-based approaches for the identification of new inhibitors, and the present study will be a useful resource for future experimental research towards the targeting of CatL in cancer therapeutics.

项与纳地美定相关的新闻（医药）

2026-04-09

·GBIHealth

盐野义&正大天晴纳地美定在大湾区获批上市

药械追踪 No.1 / 盐野义&正大天晴纳地美定在大湾区获批上市 2026年4月9日，中国生物制药（1177.HK）核心企业正大天晴独家引进的OIC治疗药物纳地美定（Naldemedine）正式获得广东省药品监督管理局批准，在粤港澳大湾区率先上市。纳地美定（Naldemedine）由盐野义制药株式会社研发，是全球首个获批的口服选择性外周μ-阿片受体拮抗剂，通过阻断肠道内阿片类药物与μ受体的结合，直接恢复肠道正常蠕动节律与肠液分泌功能，从根源上逆转OIC的病理过程。目前，纳地美定已在美国、欧盟、日本、中国港澳台地区获批上市，并获美国AGA指南、欧洲ESMO指南推荐用于OIC治疗。2025年1月，正大天晴与盐野义签订独家市场推广协议，获授予纳地美定在中国大陆地区的独家市场推广权。此前，该产品已作为临床急需药品，通过博鳌乐城国际医疗旅游先行区政策引入海南省；2025年5月，其在中国内地的新药上市申请已获中国国家药品监督管理局（NMPA）受理。 ->点击文末阅读原文，解锁完整双语新闻企业动态 No.1 /甘李药业与韩国JW制药达成博凡格鲁肽合作 2026年4月8日，甘李药业（603087.SH）宣布，与韩国头部药企JW Pharmaceutical签署独家许可协议，双方就甘李药业自主研发的胰高血糖素样肽-1受体激动剂（GLP-1RA）双周制剂——博凡格鲁肽注射液（研发代号：GZR18）在韩国的临床开发、注册申报及商业化开展合作。根据协议，JW制药将获得在韩国开发和商业化博凡格鲁肽注射液的独家权益。甘李药业将获得一次性、不可退还首付款500万美元，并可基于研发进展、监管审批及商业化等情况，收取总计7610万美元的里程碑付款，以及产品商业化后根据净销售额收取的分级特许权使用费；潜在交易总金额高达8110万美元（不含特许权使用费）。此次合作是甘李药业博凡格鲁肽注射液继拉美、印度合作后的第三笔海外授权。 ->点击文末阅读原文，解锁完整双语新闻 No.2 / 盐野义Fetroja加入美国生物盾牌计划 2026年4月8日，盐野义制药宣布，子公司Shionogi Inc. 已通过美国生物医学高级研究与发展管理局（BARDA）的 Project BioShield（生物盾牌计划）获得一份合约。该合约涉及斐铁嘉（头孢德罗），将其作为对抗难治性革兰氏阴性菌感染及对国家卫生安全构成高优先级生物威胁的病原体的关键应对措施。合约初始资金为1.19亿美元，包含多年期选项，总额最高可达4.82亿美元。该合约将通过资助 Shionogi Inc. 在美国建立斐铁嘉药物制剂生产基地，支持斐铁嘉的采购工作，推进斐铁嘉用于治疗高优先级生物威胁病原体引起的感染，包括类鼻疽伯克霍尔德氏菌（类鼻疽）和鼠疫耶尔森氏菌（鼠疫）以及，通过向美国FDA提交补充新药申请（sNDA），将斐铁嘉的效用扩展至儿科患者的医院获得性细菌性肺炎（HABP）/呼吸机相关细菌性肺炎（VABP）。在美国，斐铁嘉已获美国FDA批准，用于治疗由某些敏感革兰氏阴性微生物引起的医院获得性细菌性肺炎（HABP）、呼吸机相关细菌性肺炎（VABP）以及复杂性尿路感染；在日本，该药获批用于治疗由碳青霉烯类抗生素耐药菌株引起的各种感染；在欧洲获批用于治疗治疗选择有限的成年人需氧革兰氏阴性菌感染；在中国获批用于治疗革兰阴性菌引起的复杂性尿路感染（cUTI），包括肾盂肾炎。 ->点击文末阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作 ▶ olivia.xu@generalbiologic.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

2026-04-09

·同写意

重磅创新药通过“港澳药械通”进入大湾区，助癌痛患者对抗OIC

2026-04-08

·正大天晴药业集团

正大天晴携手盐野义！重磅合作OIC治疗药物纳地美定大湾区获批上市

阿片类药物引起的便秘（OIC）是癌症患者中最常见的症状之一，影响了约60%-90%的使用阿片类药物止痛的癌症患者[1]。4月7日，中国生物制药（1177.HK）核心企业正大天晴独家引进的OIC治疗药物纳地美定（Naldemedine）正式获得广东省药品监督管理局批准，在粤港澳大湾区率先上市。今年3月，广州市卫生健康委员会印发《关于推进“港澳药械通”政策深入实施十条措施的通知》，标志着“港澳药械通”从政策探索迈入规模化落地的新阶段，纳地美定也成为新政发布后首批通过“港澳药械通”进入大湾区的创新药物。纳地美定（Naldemedine）由盐野义制药株式会社研发，是全球首个获批的口服选择性外周μ-阿片受体拮抗剂，通过阻断肠道内阿片类药物与μ受体的结合，直接恢复肠道正常蠕动节律与肠液分泌功能，从根源上逆转OIC的病理过程[2]。一项2周治疗期、随机、双盲、安慰剂Ⅲ期对照试验显示，纳地美定首次给药至OIC患者发生自发排便（SBM）的中位时间为4.67小时，显著优于安慰剂组（26.58小时，P＜0.0001）；纳地美定治疗组SBM应答率为71.1% ，显著高于安慰剂组（34.4%，P＜0.0001），显示0.2mg纳地美定能够有效控制OIC，持续稳定改善肠道功能。晚期癌症患者的疼痛发生率可达60%-80%，其中约1/3的患者经历过中度至重度疼痛。阿片类药物是治疗癌症患者慢性疼痛的主要方法，但60%-90%的患者会出现OIC症状，严重影响患者生活质量与治疗依从性，如何有效治疗OIC并平衡镇痛与不良反应的发生已成为临床亟需解决的问题之一。目前，临床常用于治疗OIC的泻药可能会导致恶心呕吐、腹泻腹痛等胃肠道不良反应，且治标不治本；传统阿片受体拮抗剂纳洛酮虽能减弱阿片类药物的胃肠道效应缓解便秘，但其可能因跨越血脑而降低阿片类药物的镇痛作用[3]。相较之下，纳地美定选择性作用于肠道μ-阿片受体，无电解质紊乱风险，适配OIC患者长期用药需求，并且几乎不进入中枢神经系统，未发现影响阿片类药物镇痛效果。目前，纳地美定已在美国、欧盟、日本、中国台湾及中国香港、澳门地区获批上市，并获美国AGA指南、欧洲ESMO指南推荐用于OIC治疗[4,5]。2025年1月，正大天晴与盐野义签订独家市场推广协议，获授予纳地美定在中国大陆地区的独家市场推广权。此前，该产品已作为临床急需药品，通过博鳌乐城国际医疗旅游先行区政策引入海南省；2025年5月，其在中国内地的新药上市申请已获中国国家药品监督管理局（NMPA）受理；此次，纳地美定在粤港澳大湾区获批上市，将大幅提升药物可及性，解决更多OIC患者所需。随着纳地美定全国上市进程的推进，正大天晴将依托自身商业化能力，让这款全球创新药物惠及更多OIC患者，助力提升我国肿瘤支持治疗水平。参考文献： [1] Porta-Sales J, Nabal-Vicuna M, Vallano A, et al. Have we improved pain control in cancer patients? A multicen-ter study of ambulatory and hospitalized cancer patients[J]. J Palliat Med, 2015,18(11):923-932. [2]John M, Edward J, et al. Peripherally Acting u-Opioid Receptor Antagonists for theTreatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implica-tions. [3]王玥,蒋葵.阿片类药物引起的便秘病理机制及治疗进展[J].中国肿瘤临床,2021,48(16):852-857. [4] Seth D.Crockett, Katarina B.Greer, Joel J.Heidelbaugh,et al. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation.Gastroenterology 2019;156:218–226. [5]N.Katakami, T.Harada2, T.Murata,et al.Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Annals of Oncology 29(Supplement4):iv111-iv125, 2018. ▲ 上下滑动查看更多 ● 正大天晴Pan-KRAS抑制剂TQB3205中美临床双获批 ● 突破性品种再提速！正大天晴TQ-B3234罕见病Ⅲ期临床首例入组 ● ELCC 2026｜正大天晴安罗替尼、格索雷塞联合方案再添新证，涉及非小细胞肺癌、小细胞肺癌 ● 践行爱国爱港初心，郑翔玲捐资“旺角社区客厅”正式开幕

上市批准临床3期

100 项与纳地美定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	纳地美定	A06AH05	DB11691

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
阿片类药物引起的便秘	美国	BioDelivery Sciences International, Inc.	2017-03-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
癌症疼痛	临床3期	中国	盐野义有限公司	2022-07-15
便秘	临床3期	中国	盐野义有限公司	2022-07-15
慢性疼痛	临床3期	美国	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	奥地利	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	捷克	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	德国	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	波兰	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	西班牙	Shionogi, Inc.	2013-08-29
慢性疼痛	临床3期	英国	Shionogi, Inc.	2013-08-29
胃肠功能紊乱	临床2期	美国	Shionogi, Inc.	2020-11-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04966559 (PAMORA-RAP, Pubmed \| United European Gastroenterol J)	临床3期	胰腺炎	74	Naldemedine 0.2 mg	衊遞膚鬱鬱繭鹹糧範願(醖積製醖製鬱夢製簾獵) = No differences were observed between the groups for safety outcomes 衊範獵築範簾糧網鬱艱 (網簾觸窪製顧築鏇艱鑰 ) 更多	积极	2026-02-01
				Placebo
JPRN-jRCTs031200397 (ASCO2024) 人工标引	临床3期	阿片类药物引起的便秘	99	naldemedine	範齋願簾選醖製膚窪構(窪網構積醖製鹽範遞壓) = 鏇範壓鹹獵構淵願夢襯糧糧窪選築鏇齋蓋簾觸 (壓積鏇鏇鬱膚構顧齋廠, 19.8)	积极	2024-06-02
				Placebo	範齋願簾選醖製膚窪構(窪網構積醖製鹽範遞壓) = 繭醖製鑰積蓋鏇淵網夢糧糧窪選築鏇齋蓋簾觸 (壓積鏇鏇鬱膚構顧齋廠, 20.0)
NCT04355169 (CTgov)	临床2期	胃肠功能紊乱	2	Naldemedine (Naldemedine 1.25 mg)	鑰獵蓋獵繭壓壓淵顧獵(網繭製簾鏇製網遞艱製) = 簾構襯餘鏇齋願醖齋鏇壓廠積餘餘鹹鹽繭構齋 (淵鹽構範網蓋淵糧鏇鏇, 簾窪齋艱積選壓衊範糧 ~ 網壓觸觸廠構齋艱積積) 更多	-	2022-01-18
				Naldemedine (Naldemedine 2.5 mg)	鑰獵蓋獵繭壓壓淵顧獵(網繭製簾鏇製網遞艱製) = 觸淵繭遞蓋壓膚膚憲膚壓廠積餘餘鹹鹽繭構齋 (淵鹽構範網蓋淵糧鏇鏇, 鏇艱網窪憲網醖廠築艱 ~ 窪鏇衊鑰築製糧憲衊觸) 更多
NCT01965652 \| NCT01993940 \| NCT01965158 (Pubmed \| Drugs Aging)	临床3期	阿片类药物引起的便秘	2,328	Naldemedine 0.2 mg	窪糧壓齋鬱淵願遞簾製(範觸築膚醖窪鑰廠壓築) = 衊鑰夢襯鏇窪夢築願範齋願鹽繭製築齋窪積願 (鬱壓淵糧憲鏇選築網獵 ) 更多	-	2020-04-01
				Placebo	窪糧壓齋鬱淵願遞簾製(範觸築膚醖窪鑰廠壓築) = 獵鹽襯艱齋積選範觸鏇齋願鹽繭製築齋窪積願 (鬱壓淵糧憲鏇選築網獵 ) 更多
NCT01965652 \| NCT01993940 \| NCT01965158 (Pubmed \| J Pain Res)	临床3期	肾功能不全 \| 阿片类药物引起的便秘 \| 慢性疼痛	2,328	Naldemedine 0.2 mg	憲壓製壓鬱膚選鬱簾獵(網窪顧餘淵範顧繭襯鬱) = 膚遞鏇淵鹹鹽鹽遞構鹹願鬱積壓簾築觸選襯觸 (築鏇範襯壓遞觸衊積醖 ) 更多	-	2020-01-01
				Placebo	憲壓製壓鬱膚選鬱簾獵(網窪顧餘淵範顧繭襯鬱) = 製衊鬱餘鏇繭顧顧鬱壓願鬱積壓簾築觸選襯觸 (築鏇範襯壓遞觸衊積醖 ) 更多
UEGW2019	N/A	阿片类药物引起的便秘 \| 慢性疼痛	-	Naldemedine 0.2 mg	鬱選鑰鑰醖淵窪構醖獵(餘鹽選獵構夢齋廠廠廠) = 網膚衊淵構鏇製選構鬱繭鹹壓築憲衊獵淵遞齋 (鬱製餘繭鏇淵廠鹽糧糧 ) 更多	-	2019-10-01
				Placebo	鬱選鑰鑰醖淵窪構醖獵(餘鹽選獵構夢齋廠廠廠) = 鹹壓鹽願遞鹹艱壓選淵繭鹹壓築憲衊獵淵遞齋 (鬱製餘繭鏇淵廠鹽糧糧 ) 更多
UEGW2019	N/A	阿片类药物引起的便秘	-	Naldemedine 0.2 mg	積憲網淵憲範鹹製齋蓋(繭願願構顧夢簾積糧觸) = 願醖糧鏇選繭築醖糧窪網壓獵襯廠壓壓鬱蓋積 (鏇衊艱製鹽膚繭顧鹽鏇 ) 更多	-	2019-10-01
				Placebo	積憲網淵憲範鹹製齋蓋(繭願願構顧夢簾積糧觸) = 鹹衊廠醖鹹壓網壓艱壓網壓獵襯廠壓壓鬱蓋積 (鏇衊艱製鹽膚繭顧鹽鏇, 3.4 ~ 9.5) 更多
JPRN-JapicCTI-132340 \| JPRN-JapicCTI-111510 (ESMO2018)	临床2/3期	阿片类药物引起的便秘	-	Naldemedine 0.2mg QD	淵廠淵選淵簾範範襯網(鏇簾願壓鹽醖廠憲齋鏇) = Although the difference of the incidence of diarrhea between the groups was relatively larger in the possible disruption of BBB group, there was no difference between with or without possible BBB disruption for NRS and COWS. 製顧鬱鹽衊壓鹹遞襯憲 (構範遞製齋積願蓋構餘 )	积极	2018-10-22
				Placebo
UEGW2018	N/A	阿片类药物引起的便秘	-	Naldemedine 0.2 mg	範膚範鹹鹽遞顧餘鹹鹹(願網簾窪顧構餘襯鑰製) = TEAEs were comparable between the NAL and PBO in both LIR and non-LIR groups. The most common TEAEs were gastrointestinal-related. 襯繭憲鹹鏇窪糧衊鏇繭 (製觸鹹艱淵醖簾鏇遞廠 )	-	2018-10-01
NCT01443403 (Pubmed \| Pain Med)	临床2期	阿片类药物引起的便秘	244	Naldemedine 0.1 mg	獵簾簾範願鬱餘選網齋(製襯構齋獵憲鏇夢艱願) = 憲網築簾壓蓋蓋鑰衊鑰艱壓艱製衊積獵鏇願衊 (繭廠醖鏇範獵餘繭願衊 )	积极	2017-12-01
				Naldemedine 0.2 mg	獵簾簾範願鬱餘選網齋(製襯構齋獵憲鏇夢艱願) = 遞鹹鹹範積艱積範膚積艱壓艱製衊積獵鏇願衊 (繭廠醖鏇範獵餘繭願衊 )